Zhitong Financial App News, Huadong Pharmaceutical (000963.SZ) issued an announcement. Recently, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (hereinafter referred to as “China-US Huadong”), a wholly-owned subsidiary of the company, received the “Drug Clinical Trial Approval Notice” (Notice Number: 2024LP02317) approved and issued by the National Drug Administration (NMPA). The HDP-101 (hereinafter referred to as “Heberg Pharmidela”) was developed in collaboration with the company's German shareholding company Heidelberg Pharma AG (hereinafter referred to as “Heberg Pharmidela”) HDM2027) Clinical trial application approved.

Zhitong Financial App News, Huadong Pharmaceutical (000963.SZ) issued an announcement. Recently, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (hereinafter referred to as “China-US Huadong”), a wholly-owned subsidiary of the company, received the “Drug Clinical Trial Approval Notice” (Notice Number: 2024LP02317) approved and issued by the National Drug Administration (NMPA). The HDP-101 (hereinafter referred to as “Heberg Pharmidela”) was developed in collaboration with the company's German shareholding company Heidelberg Pharma AG (hereinafter referred to as “Heberg Pharmidela”) (HDM2027) Clinical trial application approved.